Gabrielle’s Angel Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood.

We support research that focuses on cancer prevention, detection, and treatments that are most likely to be translated into clinical trials within a 3 – 5 year period. The Foundation not only funds mainstream scientific research but also projects that combine integrative (complementary) therapies or botanical agents. These annual Medical Research Awards total $225,000 and are given over a three-year period.

In recent years, the Foundation has expanded its reach to include the funding of select pediatric oncology initiatives, music therapy programs, as well as international projects.

Gabrielle’s Angel Foundation has awarded grants totaling nearly $33 million in global giving and maintains its status as one of the largest non-governmental sources of grant support for blood cancer research in the nation.

Annual Request for Proposals

Our invitation-only grant process is sent out annually each spring. Please consult your institution to see if you are eligible to apply. Submissions are due to the Foundation office in August after which they undergo rigorous peer review by the Foundation’s Medical Advisory Board.

This panel of experts, led by Stephen D. Nimer, MD, Director of the Sylvester Comprehensive Cancer Center, selects only the nation’s most promising projects for funding. More than 80% of our grantees go on to obtain further funding thanks to early career support from Gabrielle’s Angel Foundation.

Determinations are made and all applicants notified by the first quarter of the year following application submission, if not sooner. 

While working on submissions, qualified candidates may download and reference these Frequently Asked Questions. The guidelines are the same for both our Conventional and Integrative applicants, however, please reference this additional information for all Integrative Medicine proposals

International Proposals

While we have funded research in the UK in years past, the Foundation is not currently accepting applications for consideration.

Awards

New Grants Totaling $2.95 Million Announced

In 2018, the Foundation’s Medical Advisory Board selected ten of the nation’s top junior investigators to receive our three-year, $225,000 Medical Research Award. The Foundation also announced support for nine one-year grants; the Director’s Innovation Fund at the Sylvester Comprehensive Cancer Center in Miami, FL; one ASBMT New Investigator Award; two music therapy programs; and assorted symposia and medical conferences.

Learn more about our Medical Research Award recipients & their proposed projects here. 

Collaborative Awards

In 2012, two teams of former grantees received Collaborative Grant Awards totaling $800,000 made possible by a generous gift from the Marc Rich Foundation. Each team received $400,000 over two years. Medical Advisory Board chair Stephen D. Nimer, M.D. remarked, “What is particularly exciting about these new collaborative grants is that they not only prove the value of the initial investment, they bring scientists and institutions together to significantly accelerate and broaden the impact of their work.”

Grantee Breakthroughs

“We have fostered an entire generation of cancer researchers and fueled their scientific breakthroughs,” said Medical Advisory Board Chairman, Dr. Stephen Nimer. “The future of cancer research has never been brighter and we are helping lead the way.” 

Ari Melnick, M.D. of Weill Cornell Medical College, Ross Levine, M.D. of Memorial Sloan Kettering Cancer Center and Chuan He, Ph.D. from The University of Chicago were awarded a grant for their project entitled “Decoding the hydroxymethylome of IDH and TET mutant acute leukemias.” Anthony Letai, M.D. of Dana-Farber Cancer Institute worked with Memorial Sloan Kettering’s Scott Armstrong, M.D. on a project where they propose “a completely novel approach to identifying the chemotherapy resistant subsets in [acute myelogenous] leukemia patient samples, identifying the mechanisms making them resistant to chemotherapy, and targeting those mechanisms.”

The Foundation hopes to offer more collaborative grants in the future.